Format

Send to

Choose Destination
Curr Opin Genet Dev. 2006 Feb;16(1):78-84. Epub 2005 Dec 15.

mTOR and cancer: reason for dancing at the crossroads?

Author information

1
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at the University of California Los Angeles, A7-149 Center for Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095-1732, USA. gvthomas@mednet.ucla.edu

Abstract

Recent successes using Gleevec for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors have provided proof that strategies to target signal transduction pathways mutated in human cancers can work. However, the application of this strategy to other cancers has been slow. Central to alleviating this impedance is the molecular characterization of the tumors. There is an urgent need to translate basic scientific findings into relevant, clinically applicable molecular diagnostic assays.

PMID:
16359855
DOI:
10.1016/j.gde.2005.12.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center